BDTX Black Diamond Therapeutics, Inc.

NASDAQ
$1.88

Black Diamond Therapeutics, Inc. (BDTX) is expected to report earnings on November 9, 2026, after the market close. The consensus earnings estimate is a loss of $0.03 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.4% since its last earnings release on August 5, 2026.

Black Diamond Therapeutics, Inc. Beat Consensus Estimates
Wednesday, August 5, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 4:00 PM ET
Earnings Whisper
-
vs ($0.03)
Rev est $50M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.06

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics is a precision oncology medicine company pioneering the development of novel MasterKey therapies.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.